Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Investing Activities (2018 - 2025)

10x Genomics' Cash from Investing Activities history spans 8 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 96.5% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$13.4 million, up 58.82%, while the annual FY2025 figure was -$13.4 million, 58.82% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$1.8 million at 10x Genomics, up from -$8.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $120.0 million in Q1 2023 and bottomed at -$257.6 million in Q1 2022.
  • The 5-year median for Cash from Investing Activities is -$6.6 million (2023), against an average of -$18.5 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 1444.05% in 2021 before it skyrocketed 367.75% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$27.6 million in 2021, then fell by 20.11% to -$33.2 million in 2022, then surged by 139.49% to $13.1 million in 2023, then plummeted by 493.89% to -$51.6 million in 2024, then skyrocketed by 96.5% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cash from Investing Activities are -$1.8 million (Q4 2025), -$8.8 million (Q3 2025), and -$939000.0 (Q2 2025).